[18F]FDG and [18F]FLT positron emission tomography imaging following treatment with belinostat in human ovary cancer xenografts in mice

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

[18F]FDG and [18F]FLT positron emission tomography imaging following treatment with belinostat in human ovary cancer xenografts in mice. / Jensen, Mette Munk; Erichsen, Kamille Dumong; Johnbeck, Camilla Bardram; Björkling, Fredrik; Madsen, Jacob; Jensen, Peter Buhl; Sehested, Maxwell; Højgaard, Liselotte; Kjær, Andreas.

In: B M C Cancer, Vol. 13, 168, 2013, p. 1-9.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Jensen, MM, Erichsen, KD, Johnbeck, CB, Björkling, F, Madsen, J, Jensen, PB, Sehested, M, Højgaard, L & Kjær, A 2013, '[18F]FDG and [18F]FLT positron emission tomography imaging following treatment with belinostat in human ovary cancer xenografts in mice', B M C Cancer, vol. 13, 168, pp. 1-9. https://doi.org/10.1186/1471-2407-13-168

APA

Jensen, M. M., Erichsen, K. D., Johnbeck, C. B., Björkling, F., Madsen, J., Jensen, P. B., Sehested, M., Højgaard, L., & Kjær, A. (2013). [18F]FDG and [18F]FLT positron emission tomography imaging following treatment with belinostat in human ovary cancer xenografts in mice. B M C Cancer, 13, 1-9. [168]. https://doi.org/10.1186/1471-2407-13-168

Vancouver

Jensen MM, Erichsen KD, Johnbeck CB, Björkling F, Madsen J, Jensen PB et al. [18F]FDG and [18F]FLT positron emission tomography imaging following treatment with belinostat in human ovary cancer xenografts in mice. B M C Cancer. 2013;13:1-9. 168. https://doi.org/10.1186/1471-2407-13-168

Author

Jensen, Mette Munk ; Erichsen, Kamille Dumong ; Johnbeck, Camilla Bardram ; Björkling, Fredrik ; Madsen, Jacob ; Jensen, Peter Buhl ; Sehested, Maxwell ; Højgaard, Liselotte ; Kjær, Andreas. / [18F]FDG and [18F]FLT positron emission tomography imaging following treatment with belinostat in human ovary cancer xenografts in mice. In: B M C Cancer. 2013 ; Vol. 13. pp. 1-9.

Bibtex

@article{f04a7265fcbf4ac8a9250f40dea028f3,
title = "[18F]FDG and [18F]FLT positron emission tomography imaging following treatment with belinostat in human ovary cancer xenografts in mice",
abstract = "Belinostat is a histone deacetylase inhibitor with anti-tumor effect in several pre-clinical tumor models and clinical trials. The aim of the study was to evaluate changes in cell proliferation and glucose uptake by use of 3'-deoxy-3'-[(18)F]fluorothymidine ([18F]FLT) and 2-deoxy-2-[(18)F]fluoro-D-glucose ([18F]FDG) positron emission tomography (PET) following treatment with belinostat in ovarian cancer in vivo models.",
author = "Jensen, {Mette Munk} and Erichsen, {Kamille Dumong} and Johnbeck, {Camilla Bardram} and Fredrik Bj{\"o}rkling and Jacob Madsen and Jensen, {Peter Buhl} and Maxwell Sehested and Liselotte H{\o}jgaard and Andreas Kj{\ae}r",
year = "2013",
doi = "10.1186/1471-2407-13-168",
language = "English",
volume = "13",
pages = "1--9",
journal = "B M C Cancer",
issn = "1471-2407",
publisher = "BioMed Central Ltd.",

}

RIS

TY - JOUR

T1 - [18F]FDG and [18F]FLT positron emission tomography imaging following treatment with belinostat in human ovary cancer xenografts in mice

AU - Jensen, Mette Munk

AU - Erichsen, Kamille Dumong

AU - Johnbeck, Camilla Bardram

AU - Björkling, Fredrik

AU - Madsen, Jacob

AU - Jensen, Peter Buhl

AU - Sehested, Maxwell

AU - Højgaard, Liselotte

AU - Kjær, Andreas

PY - 2013

Y1 - 2013

N2 - Belinostat is a histone deacetylase inhibitor with anti-tumor effect in several pre-clinical tumor models and clinical trials. The aim of the study was to evaluate changes in cell proliferation and glucose uptake by use of 3'-deoxy-3'-[(18)F]fluorothymidine ([18F]FLT) and 2-deoxy-2-[(18)F]fluoro-D-glucose ([18F]FDG) positron emission tomography (PET) following treatment with belinostat in ovarian cancer in vivo models.

AB - Belinostat is a histone deacetylase inhibitor with anti-tumor effect in several pre-clinical tumor models and clinical trials. The aim of the study was to evaluate changes in cell proliferation and glucose uptake by use of 3'-deoxy-3'-[(18)F]fluorothymidine ([18F]FLT) and 2-deoxy-2-[(18)F]fluoro-D-glucose ([18F]FDG) positron emission tomography (PET) following treatment with belinostat in ovarian cancer in vivo models.

U2 - 10.1186/1471-2407-13-168

DO - 10.1186/1471-2407-13-168

M3 - Journal article

C2 - 23548101

VL - 13

SP - 1

EP - 9

JO - B M C Cancer

JF - B M C Cancer

SN - 1471-2407

M1 - 168

ER -

ID: 45864120